



OPEN ACCESS

EDITED AND REVIEWED BY
Sharon R. Pine,
University of Colorado Anschutz Medical
Campus, United States

*CORRESPONDENCE

Xinshuai Wang
✉ xshuaiw@haust.edu.cn
Yuanpei Li
✉ lypli@ucdavis.edu

RECEIVED 28 November 2024

ACCEPTED 07 February 2025

PUBLISHED 18 March 2025

CITATION

Wang C, Deng S, Chen J, Xu X, Hu X, Kong D,
Liang G, Yuan X, Li Y and Wang X (2025)
Corrigendum: The synergistic effects of
pyrotinib combined with adriamycin on
HER2-positive breast cancer.
Front. Oncol. 15:1536374.
doi: 10.3389/fonc.2025.1536374

COPYRIGHT

© 2025 Wang, Deng, Chen, Xu, Hu, Kong,
Liang, Yuan, Li and Wang. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: The synergistic effects of pyrotinib combined with adriamycin on HER2-positive breast cancer

Chaokun Wang¹, Shuzhen Deng², Jing Chen¹, Xiangyun Xu¹,
Xiaochen Hu¹, Dejiu Kong¹, Gaofeng Liang², Xiang Yuan¹,
Yuanpei Li^{3*} and Xinshuai Wang^{1*}

¹Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China, ²Medical College, Henan University of Science and Technology, Luoyang, China, ³Department of Internal Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, United States

KEYWORDS

HER2 positive breast neoplasm, pyrotinib, adriamycin, synergistic, Akt

A Corrigendum on

The synergistic effects of pyrotinib combined with adriamycin on HER2-positive breast cancer

By Wang C, Deng S, Chen J, Xu X, Hu X, Kong D, Liang G, Yuan X, Li Y and Wang X (2021) *Front. Oncol.* 11:616443. doi: 10.3389/fonc.2021.616443

In the published article, there was an error in **Figure 3** as published. Due to the large number of photos taken, careless naming errors led to the accidental reuse of some images. The corrected **Figure 3** and its caption **Figure 3**. Effects of PYR and ADM on cell invasion appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 3

Effects of PYR and ADM on cell invasion. Cell invasion was analyzed with a Matrigel-coated Boyden chamber. SK-BR-3 and AU565 cells were treated with PBS, different concentrations of PYR (0.3, 3μg/ml), ADM (0.1, 0.3μg/ml) or a combination treatment(PYR+ADM) for 24 h. (A) Transwell invasion assays assessed the effect of PYR and ADM on SK-BR-3 cell invasion ability and histogram represents the statistical analysis. (B) Transwell invasion assays assessed the effect of PYR and ADM on AU565 cell invasion ability and histogram represents the statistical analysis. Original magnification was x100. Data represent the mean ± S.D. of three independent experiments. *p<0.05 and **p<0.01 compared with the PBS group, #p<0.05 and ##p<0.01 compared with the combination group.